Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 18/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16214951 | 0.90 | ABCB1 (0.32) | ABCB1 | |
| SCHEMBL16214943 | 0.82 | MAPT (0.33) | ABCB1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16377259 | 0.82 | MAPT (0.33) | ABCB1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15250846 | 0.77 | CYP1A2 (0.31) | ABCB1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15250850 | 0.72 | CYP1A2 (0.35) | ABCB1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16214952 | 0.71 | ABCB1 (0.33) | ABCB1 | |
| SCHEMBL13523562 | 0.69 | PTPN1 (0.36) | ABCB1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13523774 | 0.69 | PTPN1 (0.36) | ABCB1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13523592 | 0.67 | PTPN1 (0.35) | ABCB1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13471034 | 0.67 | ALDH1A1 (0.47) | CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346848-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8877731-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | ABCB1 1429/4885CYP1A2 3551/4885CYP2C9 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.